Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Carbon Tetrachloride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbon Tetrachloride SCHEMBL1405331 | 0.88 | — | — | |
| Carbon Tetrachloride SCHEMBL27746385 | 0.82 | — | — | |
| Methylene Chloride SCHEMBL27671201 | 0.82 | — | — | |
| Carbon Tetrachloride SCHEMBL5809125 | 0.74 | ALDH1A1 (0.40) | ALDH1A1LMNACYP2E1TSHR | |
| Cyclohexane SCHEMBL11683239 | 0.74 | ALDH1A1 (0.40) | ALDH1A1LMNACYP2E1TSHR | |
| Carbon Tetrachloride SCHEMBL2713989 | 0.71 | — | — | |
| Methylene Chloride SCHEMBL537879 | 0.68 | — | — | |
| Methylene Chloride SCHEMBL20919931 | 0.68 | — | — | |
| Methylene Chloride SCHEMBL5375622 | 0.68 | — | — | |
| Methylene Chloride SCHEMBL27610196 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101506185-B | Oxolane is [3,2-B] pyrroles-3-ketone intermediate also | 格兰泰有限公司 | 2016-06-29 | — | — | CN | disclosed |
| US-20150209349-A1 | Piperazine Compounds | AMURA THERAPEUTICS LTD (GB) | 2015-07-30 | — | — | US | disclosed |
| US-9045492-B2 | Piperazine compounds | AMURA THERAPEUTICS LIMITED (GB) | 2015-06-02 | — | — | US | disclosed |
| US-8877927-B2 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl proteinase inhibitors | GRUNENTHAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20130252969-A1 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-8501744-B2 | Piperazine compounds | AMURA THERAPEUTICS, LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8053437-B2 | Furo[3. 2-B] pyrrol derivatives | AMURA THERAPEUTICS LIMITED (GB) | 2011-11-08 | — | — | US | disclosed |
| US-8039641-B2 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | AMURA THERAPEUTICS LIMITED (GB) | 2011-10-18 | — | — | US | disclosed |
| US-20110077254-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-03-31 | — | — | US | disclosed |
| US-7846935-B2 | Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2010-12-07 | — | — | US | disclosed |
| US-7799791-B2 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20100216811-A1 | FURO[3. 2-B] PYRROL DERIVATIVES | AMURA THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-7737150-B2 | Furo[3, 2-b] pyrrol derivatives | AMURA THERAPEUTICS LIMITED (GB) | 2010-06-15 | — | — | US | disclosed |
| US-20100010009-A1 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors | GRUNENTHAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20090203714-A1 | Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090197817-A1 | Tetrahdrofuro[3,2-B] pyrrol-3- one as cathepsin k inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090192170-A1 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192322-A1 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090186906-A1 | N-((S)-4,4-dimethyl-1-oxo-1-((3aS,6aR)-3-oxo-dihydro-2H-furo[3,2-b]pyrrol-4(5H6H, 6aH)-yl)pentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide; treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, bone cancer | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186831-A1 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216811-A1 | FURO[3. 2-B] PYRROL DERIVATIVES | THPO, COL2A1, COL1A1 | ALDH1A1 2420/4885LMNA 2038/4885CYP2E1 1267/4885 |
| US-20090186906-A1 | N-((S)-4,4-dimethyl-1-oxo-1-((3aS,6aR)-3-oxo-dihydro-2H-furo[3,2-b]pyrrol-4(5H6H, 6aH)-yl)pentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide; treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, bone cancer | COL2A1, COL1A1, PTMS | ALDH1A1 1586/4885LMNA 1457/4885CYP2E1 733/4885 |
| US-20090197817-A1 | Tetrahdrofuro[3,2-B] pyrrol-3- one as cathepsin k inhibitors | CTSS, CTSK, TMPRSS6 | ALDH1A1 3885/4885LMNA 3875/4885CYP2E1 2124/4885 |
| US-20090192170-A1 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors | COLGALT1, COL2A1, ABCB1 | ALDH1A1 1024/4885LMNA 2649/4885CYP2E1 1226/4885 |
| US-20090203714-A1 | Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors | CTSB, CTSS, CTSL | ALDH1A1 1577/4885LMNA 1885/4885CYP2E1 1077/4885 |
| US-20090186831-A1 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | TMPRSS6, CCR6, MMP8 | ALDH1A1 4012/4885LMNA 4391/4885CYP2E1 1731/4885 |
| US-20150209349-A1 | Piperazine Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM1, CHRM5 | ALDH1A1 3062/4885LMNA 2350/4885CYP2E1 376/4885 |
| US-20110077254-A1 | COMPOUNDS | CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 | ALDH1A1 3326/4885LMNA 1409/4885CYP2E1 307/4885 |
| US-20130252969-A1 | Compounds | CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 | ALDH1A1 3315/4885LMNA 1399/4885CYP2E1 311/4885 |
| US-20100010009-A1 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors | ABCB1, COLGALT1, SLC40A1 | ALDH1A1 910/4885LMNA 2672/4885CYP2E1 1172/4885 |
| US-20090192322-A1 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | CYP4F8, CYP2C8, AVPR1B | ALDH1A1 485/4885LMNA 3230/4885CYP2E1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.